読み込み中
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
前日終値
$4.33
+$0.13 · +3.10%
時間外
$4.33
$0.00 · 0.00%
10月9日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
日中レンジ
現在 $4.33
52週レンジ
現在 $4.33
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
71
割安
センチメント
64
強気
リスク
56
やや高いリスク
モメンタム
56
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
日中レンジ
現在 $4.33
52週レンジ
現在 $4.33
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 200万 USD | — | 134万 USD | 270.3万 USD | 270.3万 USD |
| 売上原価 | 198.7万 USD | — | — | — | — |
| 粗利益 | 1.3万 USD | — | 134万 USD | 270.3万 USD | 270.3万 USD |
| 研究開発 | 638.1万 USD | 632.4万 USD | 897.1万 USD | 2763.9万 USD | 2098.9万 USD |
| 販売・一般管理 | 872万 USD | 645.7万 USD | 813.8万 USD | 1566.2万 USD | 593.7万 USD |
| 営業費用 | 1510.1万 USD | 1278.1万 USD | 1710.9万 USD | 4330.1万 USD | 2692.6万 USD |
| 受取利息 | 237.3万 USD | 498.3万 USD | 802.6万 USD | 357.3万 USD | 34.7万 USD |
| 支払利息 | — | 85.3万 USD | 358万 USD | — | — |
| 減価償却費と償却費 | 12.1万 USD | 19.3万 USD | 19.6万 USD | 5.8万 USD | 7.7万 USD |
| 営業利益 | −1508.8万 USD | −1278.1万 USD | −1576.9万 USD | −4059.8万 USD | −2422.3万 USD |
| 純利益 | 6405万 USD | −1906万 USD | 552.5万 USD | −3776.4万 USD | −2223.8万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 配当落ち日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
配当 | 2026年1月16日 | $0.25Special | 2026年1月16日 | 2026年1月26日 |
配当落ち 2026年1月16日
$0.25
Special
2026年1月16日基準 · 支払日 2026年1月26日
この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM360.68万0.00%782.66億 USD0.19%$278.94+0.49%
iShares Russell 2000 Value ETFIWN132.89万0.01%138.48億 USD0.24%$210.87-0.04%
Vanguard Russell 2000 ETFVTWO98.62万0.01%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC45.77万0.03%13.17億 USD0.60%$183+0.11%
Dimensional - US Small Cap ETFDFAS25.67万0.00%338.69億 USD0.31%$78.35+0.32%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC25.29万0.02%10.45億 USD0.20%$86.29+0.43%
Dimensional - US Core Equity 2 ETFDFAC25.15万0.00%885.96億 USD0.21%$45.33+0.49%
Avantis U.S. Small Cap Equity ETFAVSC23.36万0.01%30.61億 USD0.25%$69.98+0.03%iShares Russell 2000 ETFIWMiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCDimensional - US Core Equity 2 ETFDFACAvantis U.S. Small Cap Equity ETFAVSCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
